ClinicalTrials.gg
RecruitingNCT06150898KePreStUpdated Oct 9, 2026

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt)

A Phase 2 interventional study of Prospective data and sample collection and Ketorolac 10 Mg Oral Tablet in Early-stage Breast Cancer and Estrogen-receptor-positive Breast Cancer, sponsored by Jules Bordet Institute. Recruiting at 1 site in Belgium. Open to female participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2026-10-09.

Sponsored by Jules Bordet Institute · Phase 2, Interventional, and Other

How we know

From the registry’s dates

  • Started May 2025; still recruiting 1 year 6 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
112
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
Female
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 42 studies in Breast Neoplasms by Jules Bordet Institute — 7 open to participants now, 9 under way, none of them phase 3. Breast Neoplasms · Jules Bordet Institute.

Planned enrollment
11th of 38
112 · median 49
Started
2025
with 2 others
Phase 2
25 of 42
2 open now
Registered
34th of 42
by date

Among the 42 studies in Breast Neoplasms by Jules Bordet Institute, this one is the 11th largest by planned enrollment of the 38 interventional ones that give a count, is one of 3 that started in 2025, is one of 25 in phase 2, and was the 34th registered.

Breast Neoplasms

14,855 studies on the registry are indexed under Breast Neoplasms; 3,321 are open to participants now.

Browse Breast Neoplasms studies →

Open to participants now

7 of the 42 studies in Breast Neoplasms by Jules Bordet Institute are open now, in 10 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 7 open studies →

Who these studies take

Of the 2,403 Breast Neoplasms studies recruiting now, 1,574 (66%) set no upper age limit and 591 (25%) stop at 75 or younger; 103 take children under 18; 215 take healthy volunteers.

This study: 18 Years to 70 Years · female · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 42 studies in Breast Neoplasms by Jules Bordet Institute, or all of them as a file.
02

Study summary

Out of all proportion to its short duration, the perioperative period is critical in determining the long-term outcome of cancer.

To contribute to a better understanding of the neural and inflammatory mechanisms underlying this issue, we aim to implement a novel intervention based on the preoperative use of non-steroidal anti-inflammatory drugs (NSAIDs) with or without an anti-epileptic drug.

Our goal is to understand and transform the perioperative window from being a facilitator of metastatic progression to arresting and/or eliminating residual disease using repurposing drugs

Read the detailed description

The perioperative period presents a unique window of therapeutic opportunities to counteract minimal residual growth and dormancy escape of cancer cells. The main physiological disturbances induced by the surgery, that enhance the tumoral growth in the perioperative period, are due to the neuronal and inflammatory signaling.

We propose a therapeutic modelling of the inflammatory and neurological pathways in a phase II trial using ketorolac and pregabalin, alone or in combination. Ketorolac, a non-selective NSAIDs will target cyclooxygenase (COX)-enzymes, while pregabalin, an anti-epileptic drug will regulates the release of neurotransmitters. Moreover, both drugs have an effect on the postoperative pain and pregabalin has anxiolytic property. Thanks to this study, and through specific blockade, we want to understand how nervous and inflammatory systems remodel the tumour and systemic characteristics. To ensure an integrative analysis of those factors, patient's adiposity as well as other confounding variable will be taken into account.

03

Conditions studied

  • Early-stage Breast Cancer
  • Estrogen-receptor-positive Breast Cancer

Keywords

  • Surgery
  • Inflammation
  • Breast cancer
  • Neuronal features
  • Ketorolac
  • Pregabalin
  • Adiposity
  • Neurotransmitter
  • Nerves
04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Subjects must meet all of the following criteria in order to be eligible for this study:

  1. Age ≥ 18 years and ≤ 70 years old
  2. Female
  3. Weight ≥ 35 kg
  4. Histological diagnosis of invasive breast adenocarcinoma that is estrogen receptor positive as per the updated American Society of Clinical Oncology (ASCO) - College of American Pathologists (CAP) guidelines according to local testing with ER-positive is defined as having an immunohistochemistry (IHC) of 1% or more and/or Allred score of 3 or more
  5. Tumour size ≥ 1.5 cm, determined by diagnostic ultrasound or MRI/CT scan.
  6. Stage I, II or III disease (non-)
  7. In case of multifocal, multicentric unilateral or bilateral breast: Adenocarcinoma tumours are allowed provided that all foci are ER+ according to local testing
  8. Subject scheduled for a primary breast cancer surgery
  9. Subject is willing to provide plasma/blood and tumour samples for translational research.
  10. Subject is willing to provide tissue from a newly obtained core or excisional of the tumour that should be evaluable for central histological characterization and future molecular testing
  11. Subject is willing to take omeprazole and has no to omeprazole.
  12. Have an HEMSTOP score\<2 and conventional coagulation screening test within normal limits such as (21.6\< aPTT >28.7), international normalised ratio (1.31\<INR) and count (>100.10³/ml)
  13. Women of must agree to use of one highly effective method of prior study entry, during the course of the study and at least one months after the last administration of study treatment.
  14. Negative serum pregnancy test for women of childbearing potential (within 30 days before start of treatment)
  15. Subject is willing and able to provide written for the trial

Exclusion criteria

Exclusion Criteria:

Subjects meeting one of the following criteria are not eligible for this study:

  1. Subject planned for intraoperative radiotherapy
  2. Subject planned for immediate reconstruction
  3. BC therapy
  4. Allergy to any NSAID or gabapentinoïd
  5. Known reactions to the treatments, or any or auxiliary medicinal products or concomitant medications. Hypersensitive to peanut or soya (related to propofol )
  6. Current use of the antidiabetic agent thiazolidinedione (related to interaction with pregabalin), lithium salts, probenecid, pentoxifylline or intensive diuretic therapy.
  7. Current NSAID (> twice a week the year prior to diagnosis) or pregabalin use
  8. Previous malignant pathology within 5 years prior to inclusion or currently undergoing maintenance therapy. Exceptions include basal cell carcinoma or squamous cell carcinoma of the skin that have undergone potentially curative therapy or in situ cervical cancer.
  9. Active or history of peptic ulcer disease or gastro-intestinal bleeding or perforation
  10. Pregnancy or lactating women
  11. Chronic inflammatory disease as rheumatoid arthritis, uncontrolled asthma, chronic heart failure, , cystic fibrosis, inflammatory myopathies (e.g., idiopathic polymyositis, dermatomyositis, inclusion body myositis), inflammatory bowel disease (e.g., Crohn's disease, ulcerative colitis), McArdle's disease, multiple sclerosis, lupus, chronic inflammatory demyelinating polyneuropathy, psoriasis, thyroiditis as Graves' disease or Hashimoto's thyroiditis (unless previous surgical ablation), myasthenia gravis, vasculitis.
  12. Complete or partial nasal polyposis syndrome, Quincke's oedema, bronchospasm, asthma
  13. Known chronic infectious disease as active (defined as positive serology for Ac anti-HBc and IgM anti HBc OR Ac anti HBc and Ag HBs), active (defined as positive serology for anti-VHC and positive PCR-VHC) or active tuberculosis (included under treatment)
  14. Uncontrolled infection (defined as detectable viral loads by standard clinical assays) or controlled HIV infection (defined undetectable HIV viral loads by standard clinical assays) treated by one of following drugs: Nelfinavir, Atazanavir or Saquinavir (related to interaction with omeprazole).
  15. Infection currently treated with one of the following drugs: posaconazole, voriconazole, ketoconazole and rifampicin, unless discontinuation of treatment is planned at least 10 days prior to the start of study treatment AND with complete resolution according to expert opinion (related to interaction with omeprazole)
  16. Inadequate liver function (defined as total serum ≥ 2 x (ULN\<1.2 mg/dl) - unless documented Gilbert syndrome- AND (ALT) ≥ 2 x ULN (ULN \<32 UI/l and ULN \<33 UI/l, respectively) AND Alkaline phosphatase (ALP) ≥ 2.5 x ULN (ULN=104 UI/l))
  17. Cirrhosis or severe hepatitis.
  18. Renal impairment (defined as \<90ml/min/1.73m² or serum creatinine > 442 μmol/l or > 5 mg/dL) or single kidney or previous renal surgery
  19. Subject with history of (severe) renal toxicity with an NSAID
  20. Subject with a recent history of operations associated with a high risk of bleeding
  21. Previous, ongoing or suspected cardiovascular disease defined as history of ischemic heart disease or heart failure or uncontrolled high blood pressure (Systolic ≥160mmHg and/or diastolic ≥100mmHg) or peripheral arterial disease or cerebrovascular disease
  22. Subject with a recent history of surgery associated with a high risk of bleeding
  23. Hemostasis disorder as haemophilia, Von Willebrand disease, constitutional thrombopathies or thrombocytopenia (defined as count \< 100 000/mm³), current /planned anticoagulant or anti-platelet therapy.
  24. Inadequate bone marrow function (defined as \<1000/μL and platelet count \<100'000/μL)
  25. Systemic treatment (defined as systemic corticotherapy or anti-rejection treatment or interferon therapy) within the 2-years prior diagnosis
  26. Psychiatric disease or antipsychotic/ antidepressant use
  27. Epilepsy or any current anti-epileptic drug use
  28. Obstructive sleep apnea
  29. ASA≥3
Terms in these criteria, in plain language(23)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

05

Study design

Phase
Phase 2
Primary purpose
Other
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
112 participants (estimated)

Study arms

  • Experimental
    No pre-operative treatment

    Control group: Standard of care Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

    Procedure: Prospective data and sample collection · Drug: Omeprazole 20mg Capsule

  • Experimental
    Pre-operative ketorolac

    Investigational Medicinal Product (IMP): Ketorolac Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

    Procedure: Prospective data and sample collection · Drug: Ketorolac 10 Mg Oral Tablet · Drug: Omeprazole 20mg Capsule

  • Experimental
    Pre-operative pregabalin

    Investigational Medicinal Product (IMP): Pregabalin Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

    Procedure: Prospective data and sample collection · Drug: Pregabalin 75mg · Drug: Omeprazole 20mg Capsule

  • Experimental
    Pre-operative ketorolac and pregabalin

    Investigational Medicinal Products (IMPs): Ketorolac and pregabalin Number of subjects: 28 (14 lean patients, defined as Body mass index \<25 kg/m², and 14 overweight/obese patients, defined as BMI ≥25 kg/m² )

    Procedure: Prospective data and sample collection · Drug: Ketorolac 10 Mg Oral Tablet · Drug: Pregabalin 75mg · Drug: Omeprazole 20mg Capsule

Interventions

  • ProcedureProspective data and sample collection

    Core-needle biopsy of the breast (pre-treatment), surgical sample collection (post-treatment), extra collection of blood samples (pre- and post-treatment), measurements of adiposity, lifestyle questionaire

  • DrugKetorolacStudies of KetorolacKetorolac pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 10 mg film-coated tablets of ketorolac tromethamine three times a day, for five days before the surgery

  • DrugPregabalinStudies of PregabalinPregabalin pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 75 mg of pregabalin hard capsule twice a day, for seven days before the surgery

  • DrugOmeprazoleStudies of OmeprazoleOmeprazole pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Patients will receive 20 mg of omeprazole once a day on an empty stomach, for five days before the surgery

    Also known as: Auxiliary medicinal product

06

What researchers measure

Primary outcomes

  1. To detect a reduced increase in systemic inflammation (from baseline to up to 24 hours after surgery) using peri-operative ketorolac

    Plasma multiplex technology using cytometric bead arrays

    Time frame: Up to 24 hours after surgery

  2. To detect a reduced increase in systemic neurotransmitters (from baseline to up to 24 hours after surgery) using peri-operative pregabalin

    Liquid Chromatography coupled to tandem Mass Spectrometry (LC-MS/MS)

    Time frame: Up to 24 hours after surgery

  3. Change in biomarkers of metastasis at surgery from baseline

    Transcriptome profile and bioinformatic analysis

    Time frame: At surgery

  4. Change in tumoral immune cells recruitment at surgery from baseline

    Characterization of Tumour-infiltrating leukocyte subpopulations using RNA sequencing analysis from fresh frozen tissue sections

    Time frame: At surgery

  5. Change in tumoral neurogenesis at surgery from baseline

    Level of neurogenesis markers using RNA sequencing analysis from fresh frozen tissue section

    Time frame: At surgery

  6. Change in tumoral neurotransmitters level at surgery from baseline

    Using RNA sequencing analysis from fresh frozen tissue sections

    Time frame: At surgery

  7. Change in Peripheral Blood Mononuclear Cells at surgery from baseline

    Fluorescence activated cell sorting (FACS) analysis

    Time frame: At surgery

  8. Change in systemic neuro-inflammatory mediators at surgery from baseline

    Plasma multiplex technology using cytometric bead arrays

    Time frame: At surgery

  9. Change in systemic neurotransmitters at surgery from baseline

    Plasma multiplex technology using cytometric bead arrays

    Time frame: At surgery

Secondary outcomes

  1. Change in anxiety level at surgery from baseline

    Generalized Anxiety Disorder - 7 (GAD - 7) Anxiety score (natural number, range\[0 - 21\]. A score comprised between 0 - 4 indicates a minimal anxiety, 5-9 a mild anxiety, 10-14 a moderate anxiety and a 15-21 in a severe anxiety.

    Time frame: At surgery

  2. Post-operative pain

    Consumption of morphine delivered by a programmable patient-controlled analgesia (PCA) infusion pump (number of requested and effectively delivered bolus/ 24h)

    Time frame: Up to 48 hours after surgery

Other outcomes

  1. Body Mass Index

    Calculated: body mass (kg) divided by height squared (m²)

    Time frame: The day before surgery

  2. Body composition

    Calculated from multiple frequency bio-impedance measurements (in %, range \[0 - 100\])

    Time frame: The day before surgery

  3. Waist-to-hip ratio

    Waist circumference (cm) divided by hip circumference (cm)

    Time frame: The day before surgery

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started May 2025 (actual). Primary completion is estimated for Apr 2027, 23 months after the start.

Of 1,070 non-industry phase 2 interventional studies under Breast Neoplasms, half reached primary completion within 56 months of starting (the median), counting those still running; a quarter within 34 and three quarters within 89. This study's planned 23 months is below that.

Counting every sponsor, half of 1,302 studies reached it within 51 months; a quarter within 30 and three quarters within 83.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 30, 2022
First posted
Nov 29, 2023
StartActual
May 12, 2025
Primary completionEst.
Apr 20, 2027
CompletionEst.
Oct 2027
Last update
Oct 9, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Minor edits
Nothing that changes what the study is or who can join. Edited: index terms, verification date and oversight details
1 update, last Oct 9, 2026
Show all 1 update
  1. Oct 9, 2026
    Minor edits only
    + 3 other changes: index terms, verification date and oversight details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06150898
Collaborators
KU Leuven
Responsible party
Sponsor
First posted
Nov 29, 2023
Start date
May 12, 2025
Primary completion
Apr 20, 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Oct 9, 2026

Study contacts

Imane Bachir, MD
Contact
imane.bachir@bordet.be
+3225413601
Marion Maetens, PhD
Contact
marion.maetens@kuleuven.be
+3216321194
Christine Desmedt, PhD
study chair · KU Leuven
Imane Bachir, MD
study chair · Jules Bordet Institute

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ketorolac · Pregabalin

Start the discussion